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Abstract: In an earlier work, the role of heat shock protein
(Hsp60) in the pathogenesis of ulcerative colitis (UC) was
suggested by its signiﬁcant increase in the pathological mucosa
parallel with an increase in inﬂammatory cells. More data in this
direction are reported in this work. We analyzed by immunohis-
tochemistry biopsies of colon tissue from 2 groups of patients with
UC and treated with either 5-aminosalicylic acid (5-ASA) alone or
in combination with a probiotic. We looked for inﬂammatory
markers and Hsp60. Both the treatments were eﬀective in reducing
symptoms but the group treated with both 5-ASA and probiotics
showed better clinical results. Amelioration of symptoms was
associated with reduction of both inﬂammation and Hsp60, a
reduction that was most marked in the group treated with 5-ASA
and probiotics. The levels of Hsp60 positively correlated with
those of CD68-positive cells, and double immunoﬂuorescence
showed a high index of colocalization of the chaperonin and CD68
in lamina propria. Immunoelectron microscopy showed that
Hsp60Fclassically a mitochondrial proteinFwas abundantly
also present in cytosol in biopsies taken at the time of diagnosis,
but not after the treatment. Our data suggest that Hsp60 is an
active player in pathogenesis of UC and it can be hypothesized
that the chaperonin is responsible, at least in part, for initiation
and maintenance of disease.
Key Words: Hsp60, chaperonin, ulcerative colitis, macrophages,
CD68, inﬂammation, innate immunity
(Appl Immunohistochem Mol Morphol 2011;00:000–000)
Heat shock proteins (Hsps) are a large family of mole-cules highly conserved during evolution and, thus,
are present in all living species, from archaea and bacteria
to humans.1 This is probably owing to the fact that stress
is an ancestral phenomenon and primordial cells had the
need to develop antistress proteins like Hsps. Many Hsps
are also chaperones and they are involved in folding,
refolding, translocation, and degradation of intracellular
proteins, both under normal and stress conditions.2 Des-
pite the fact that not all Hsps are chaperones and, con-
versely, not all chaperones are Hsps, the terms Hsp and
chaperone are used interchangeably in the literature, and
we will do so here.
The importance of Hsps/chaperones in protein
homeostasis and other cellular processes such as innate
immunity is well documented and, therefore, their quanti-
tative or qualitative alterations owing to, for instance,
mutation, aberrant posttranslational modiﬁcation, or
gene dysregulation, can cause a variety of diseases now
known as chaperonopathies.3 Further proof of the impor-
tance of Hsps/chaperones is that they can be considered
therapeutic agents in replacement therapy (chapero-
notherapy) or as targets for inhibition if they play a
pathogenetic role.4 Probable examples of the latter case,
that is, chaperones as agents of disease rather than pro-
tection against it, are inﬂammatory bowel diseases
(IBDs). For example, we found that Hsp60 and Hsp10Copyright r 2011 by Lippincott Williams & Wilkins
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are increased in the aﬀected mucosa in Crohn disease and
ulcerative colitis (UC).5
Hsp60 is among the most conserved Hsps/chaper-
ones.6 It has been classically described as a mitochondrial
protein,7 although many studies have showed that it also
resides outside mitochondria, for example in the cytosol,
vesicles, and cell membrane.8,9 The presence and integrity
of Hsp60 in mitochondria are crucial for cell survival,10–12
and at least 2 serious human genetic chaperonopathies
occur because of the mutation of the hsp60 gene.13,14 In
addition, increased levels of Hsp60 are a hallmark of a
number of neoplasms15 and autoimmune disorders.16,17 In
some of these pathologies, not only Hsp60 overexpression
has been documented, but also an unusual subcellular
localization has been described18–21 and, consequently, a
pathogenetic role for the chaperonin has been proposed.
We have previously found increased levels of Hsp60
in a number of human neoplasms, including large bowel
carcinomas, and these levels were correlated with the stage
and grade of the disease.22,23 As mentioned above, more
recently we studied a series of patients with IBDFa
condition considered high-risk for cancer develop-
mentFand we found increased levels of Hsp60 in both
Crohn disease and UC, postulating that this protein could
be implicated in their pathogenesis by triggering and/or
maintaining inﬂammation.5 We found that the increased
levels of the chaperonins were associated with an increase in
inﬂammatory cells in both pathologies by comparison with
normal mucosa. We also found that Hsp60 and Hsp10
occurred in the cytoplasm of mucosal epithelial cells in the
2 diseases but not in nonaﬀected tissue from controls. These
ﬁndings, together with data from many laboratories
demonstrating a role of chaperones in the etiology and
pathogenesis of various diseases, as brieﬂy mentioned in the
initial paragraphs of this section, indicated that Hsp60 and
Hsp10 deserve careful scrutiny as possible IBD causative
agents. With this in mind, we proceeded to explore more in
depth the possible participation of chaperonins in the
initiation, progression, and relapse of IBD. For this pur-
pose, we focused on 1 disease, UC, and on 1 chaperonin,
Hsp60. It was important to conﬁrm the increase in Hsp60
in diseased mucosa of UC and to determine whether the
chaperonin would associate with cells that initiate the
innate immune response, chieﬂy inﬂammatory cells, or with
cells involved in the adaptive immune response, chieﬂy
antibody production. Furthermore, it was important to
establish if treatments that bring about clinical remission of
UC also have an inﬂuence on Hsp60 and its associated
immune response cells, innate or adaptive. A parallelism
between clinical remission with decrease in the chaperonin
levels and inﬂammation in the aﬀected tissue would
strongly support the notion that Hsp60 can contribute to
disease and, also, that Hsp60 has to be seriously considered
as a pathogenetic molecule in UC under certain circum-
stances, for example when it gains the extracellular space
and interacts with inﬂammatory cells.
We report here the results of this detailed analysis of
Hsp60 and inﬂammatory cells in the colon mucosa of
patients with UC.
MATERIALS AND METHODS
Patients
We studied 40 patients with mildly to moderately
active UC. Disease activity was assessed using the Mayo
Score system from 0 to 12.24 Mildly to moderately disease
activity was deﬁned by a score of 4 to 10. In these patients,
we performed a randomized clinical study to compare the
eﬃcacy of the treatment for 6 months with 1.2 or 2.4 g/d
(depending on the disease severity) of mesalazine or 5-
aminosalicylic acid (5-ASA, Asacol, Giuliani, Italy) to that
of the treatment with both 5-ASA and 1 capsule/day of
probiotics (Acronelle, Bromatec, Italy).
All patients underwent ﬂexible colonoscopy at the
time of diagnosis and again at the 6-month follow-up visit
(end point). During both the occasions, biopsies were
taken, formalin-ﬁxed, and sent to the pathologist for
routine diagnostic examination. A small sample from
each specimen was ﬁxed in Karnofsky solution for im-
munoelectron microscopy (see below). Informed consent
was obtained from all patients at the time of biopsy and
the study was approved by the Ethics Committee of the
University Hospital of Palermo, Italy.
Tissue Preparations
Specimens for immunohistochemistry and double
immunoﬂuorescence analyses (see below) were paraﬃn-
embedded and 4 to 5 mm sections were obtained from all
cases. We also studied 20 specimens of formalin-ﬁxed
paraﬃn-embedded normal colon mucosa from archival
tissue, as controls.
Samples for immunoelectron microscopy were
embedded in London Resin-white (Electron Microscopy
Sciences, Hatﬁeld, PA) following the manufacturer’s
protocols, ultracut with an ultramicrotome (Reichert
Ultracut E), and mounted on 150-mesh uncoated gold
grids for immunogold labeling (see below).
Immunohistochemistry
Immunostaining was done on 4 to 5mm tissue
sections with a battery of antibodies, which are listed
in Table 1, using an avidin-biotin complex kit (LSAB2,
DAKO, Carpinteria, CA). Appropriate positive controls,
as well as nonimmune serum for negative controls, were
run concurrently. 3-30-diaminobenzidine (DAB chromogen
solution, DAKO) was used as developer chromogen.
Nuclear counterstaining was done using hematoxylin
(DAKO).
Three independent observers (F.C., M.Z., and
A.M.) examined the specimens in a blind (code marked)
approach and performed a quantitative analysis to deter-
mine: (a) the percentage of cells positive for the leukocyte
markers CD3, CD4, CD8, CD20, and CD68 in colon
lamina propria, and (b) the percentage of cells positive for
Hsp60 both in epithelium and lamina propria of colon
mucosa. All the observations were made at a magniﬁca-
tion of 400 and the means of triplicate counts were
used for statistical analyses.
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Double Immunofluorescence
Tissue sections were dewaxed in xylene, rehydrated
in ethanol, washed in phosphate buﬀer solution (PBS),
incubated with unmasking solution (tri-sodium citrate
10mM, 0.05% tween 20) for 10min at 581C, and treated
with blocking solution (3% bovine serum albumin in
PBS) for 30 minutes at 241C. Then, the sections were
incubated with the ﬁrst primary antibody (mouse anti-
CD68; see Table 1 for details) overnight at 41C. The fol-
lowing day, some sections were incubated with the second
primary antibody (rabbit anti-Hsp60; see Table 1 for
details) overnight at 41C. After the incubations with the
antibodies, the sections were washed 2 times in PBS, and
were incubated with ﬂuorescent secondary antibodies:
mouse IgG antibody conjugated with ﬂuorescein isothio-
cyanate (Sigma-Aldrich, Inc, Milan, Italy) and/or rabbit
IgG antibody conjugated with Texas Red (Gene Tex Inc,
Irvine, CA) for 1 hour at 241C. The nuclei were
counterstained with Hoechst (Sigma-Aldrich, Inc, Milan,
Italy) for 15 minutes at 241C. Finally, the sections were
covered with a drop of PBS, the slides were mounted with
cover slips, and readings and imaging were immediately
performed with a Leica DM5000 upright ﬂuorescence
microscope (Leica Microsystems, Heidelberg, Germany).
Two independent observers (F.C., and A.M.G.) examined
the specimens in a blind (code marked) approach and
performed a quantitative analysis to evaluate the number
of cells that showed colocalization of CD68 and Hsp60
in lamina propria. All the observations were made at
a magniﬁcation of 400 and the means of the duplicate
counts were used for statistical analyses.
Statistical Analysis
Data obtained from immunohistochemistry and im-
munoﬂuorescence evaluations were plotted using Microsoft
Excel software (Microsoft Italia, Milan, Italy). Statistical
analyses were carried out using the GraphPad Prism
4.0 package (GraphPad Inc, San Diego, CA) and T
A
B
L
E
2
.
Im
m
u
n
o
h
is
to
ch
e
m
ic
a
l
Q
u
a
n
ti
fi
ca
ti
o
n
F
S
h
o
w
n
in
M
e
a
n
P
e
rc
e
n
ta
g
e
W
it
h
(
±
)
S
ta
n
d
a
rd
D
e
vi
a
ti
o
n
F
o
f
C
e
lls
W
it
h
th
e
V
a
ri
o
u
s
M
a
rk
e
rs
E
x
a
m
in
e
d
in
th
e
5
G
ro
u
p
s
S
tu
d
ie
d
5
-A
S
A
a
t
th
e
T
im
e
o
f
D
ia
g
n
o
si
s
5
-A
S
A
+
P
B
a
t
th
e
T
im
e
o
f
D
ia
g
n
o
si
s
5
-A
S
A
A
ft
er
6
m
o
5
-A
S
A
+
P
B
A
ft
er
6
m
o
N
o
rm
a
l
M
u
co
sa
(C
o
n
tr
o
ls
)
C
D
3
7
1
.3
±
1
4
.6
7
1
.8
±
1
6
.7
5
3
.6
±
1
0
.0
3
0
.4
±
7
.4
2
4
.9
±
9
.3
C
D
4
6
7
.9
±
1
4
.2
6
5
.8
±
1
3
.6
4
1
.7
5
±
9
.2
3
2
.2
±
8
.5
2
5
.5
5
±
7
.8
C
D
6
8
2
5
.0
5
±
8
.7
2
6
.6
±
6
.1
1
6
.7
5
±
4
.2
1
2
.3
5
±
5
.9
1
0
.0
5
±
5
.5
H
sp
6
0
in
ep
it
h
el
iu
m
8
5
.1
±
1
6
.2
8
4
.1
5
±
1
4
.5
3
3
.9
±
7
.1
1
6
.2
5
±
6
.2
3
.7
5
±
2
.5
H
sp
6
0
in
la
m
in
a
p
ro
p
ri
a
3
1
.1
5
±
7
.3
3
2
.8
±
6
.5
1
7
.7
±
5
.7
9
.4
±
3
.3
2
.4
±
2
.0
5
-A
S
A
in
d
ic
a
te
s
5
-a
m
in
o
sa
li
cy
li
c
a
ci
d
(m
es
a
la
zi
n
e)
;
P
B
,
p
ro
b
io
ti
cs
.
TABLE 1. Characteristic of the Antibodies Used in This Study
Antibody
Speciﬁc
for: Supplier
Catalog
Number Source Dilution
Hsp60 SIGMA H4149 Mouse 1:300*
Hsp60 SIGMA H4149 Mouse 1:30w
Hsp60 StressGen SPA-805 Rabbit 1:100z
CD3 Novocastra NCL-L-
CD3-PS1
Mouse 1:100
CD4 Novocastra NCL-L-
CD4-1F6
Mouse 1:100
CD8 Novocastra NCL-L-
CD8-295
Mouse 1:100
CD20 Novocastra NCL-L-
CD20-L26
Mouse 1:100
CD68 Novocastra NCL-CD68-
KP1
Mouse 1:100
*For immunohistochemistry.
wFor immunoelectron microscopy.
zFor double immunoﬂuorescence microscopy.
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nonparametric tests to compare groups that did not ﬁt to
the normal distribution. To evaluate the signiﬁcance of
diﬀerences between groups, the Wilcoxon test was used.
Correlation analysis between Hsp60 and inﬂammatory
markers was performed using the Pearson test, which gives
a correlation coeﬃcient (Pearson “r”) and a “p” value that
measures the signiﬁcance of the analyzed correlation. For
correlation graphs, linear regression was also calculated to
reﬂect the type of correlation between the chosen variables.
Data were considered signiﬁcant at an a level of 5%. To
have an indication on the variability of immunoreactivity
data obtained by the diﬀerent observers, the coeﬃcient of
variation was calculated using both the interobserver and
intraobserver k statistics.
Immunoelectron Microscopy
London Resin-white resin embedding combined with
postembedding immunogold labeling was used to localize
Hsp60 within cells of colon mucosa by transmission
electron microscopy. Brieﬂy, a small fragment of colon
tissue from patients who underwent ﬂexible colonoscopy
was excised from biopsy, cut into smaller pieces, postﬁxed
with 0.5% glutaraldehyde/2% paraformaldeyde (Karnofs-
ky ﬁxative) in sucrose-cacodylate buﬀer, and ultrathin
sections were prepared as per standard procedures. Then,
the ultrathin sections were treated with primary anti-Hsp60
antibody (see Table 1 for details) and secondary 10-nm
gold-conjugated Aurion anti-mouse antibody (Electron
Microscopy Sciences, Hatﬁeld, PA) following the proce-
dure described by others.8 Finally, the mesh were observed
in a JEOL 1220 transmission electron microscope.
RESULTS AND DISCUSSION
Clinical Results
Patients with mild-to-moderate UC were random-
ized into 2 groups: one having patients treated only with
5-ASA and the other having patients treated with both 5-
ASA and probiotics (5-ASA+PB). Both the treatments
lasted for 6 months. Clinical results are summarized in
Figure 1. At the time of diagnosis, both groups of patients
had a Mayo Score between 4 and 10 (mean of 5-ASA
patients: 6.73; mean of 5-ASA+PB patients: 6.86). After
the treatment, both the groups showed a signiﬁcant re-
duction (P<0.001) in their scores (between 0 and 3; mean
of 5-ASA patients: 2.06; mean of 5-ASA+PB patients:
1.26). In addition, the diﬀerence between the scores after
the 2 treatments (2.06 vs. 1.26) was also signiﬁcant
(P<0.05). Therefore, the combination 5-ASA+PB was
more eﬀective for score reduction than 5-ASA alone.
These results are in agreement with other studies which
showed that diﬀerent combinations of probiotics are quite
eﬀective in ameliorating the symptoms of patients with
UC.25–27
Immunohistochemistry of Inflammatory
Markers
To assess the inﬂammatory cell component in all
examined specimens, we used a panel of antibodies that
FIGURE 1. Clinical results. The bars show the Mayo Score
of the 2 groups of patientsFtreated with mesalazine only
(5-ASA) or with both 5-ASA and probiotics (PB)Fat the time
of diagnosis (T0) and at the 6-month end point (T1). Both
treatments gave a significant reduction of the score (see text).
Noteworthy is that the score after 5-ASA+PB treatment was
significantly lower (P<0.05) than after treatment with 5-ASA
alone indicating that the treatment with the drug-probiotics
combination was more efficacious than the drug alone.
FIGURE 2. Immunohistochemical results for inflammatory markers. The bars show the levels of CD3, CD4, and CD68 in biopsies
from patients before and after treatment with either 5-ASA alone or with the combination 5-ASA+PB. Both treatments produced a
significant reduction (P<0.01) in the percentage of inflammatory cells. The reduction of inflammatory cells after treatment with 5-
ASA+PB was significantly greater (P<0.01, P<0.05, and P<0.05 for, respectively, CD3, CD4, and CD68) than after treatment with
5-ASA alone. Bars: dark blue, 5-ASA at the time of diagnosis; red, 5-ASA+PB at the time of diagnosis; green, 5-ASA after 6 months;
violet, 5-ASA+PB after 6 months; light blue, normal mucosa (controls). 5-ASA indicates 5-aminosalicylic acid (mesalazine); PB,
probiotics.
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recognize the most relevant leukocytes, considering the
objectives of our work (Table 1). All the molecular
markers that we searched were expressed with variable
percentages in all the examined tissues. We found signi-
ﬁcant variations only for CD3, CD4, and CD68 markers.
Results are summarized in Table 2 and Figure 2. The
percentages of these 3 molecular markers were highest at
the time of diagnosis without diﬀerences between groups,
but they decreased signiﬁcantly after the treatments
(P<0.01). In addition, the diﬀerences between groups
after treatment were signiﬁcant (P<0.01 for CD3;
P<0.05 for CD4; P<0.05 for CD68, Fig. 2). We also
found a signiﬁcant diﬀerence for the levels of CD3, CD4,
and CD68 when both the treated groups were compared
with normal mucosa (controls), with the exception of
CD3 and CD4 when 5-ASA+PB patients were compared
with controls (data not shown). Figure 3 shows a series
of representative immunohistochemical pictures of these
3 markers. The greater numbers of positive cells were
localized in lamina propria and only these were con-
sidered for our counts. These results demonstrated that
the amelioration of clinical symptoms (see above) is
associated with a reduction of inﬂammatory cells in colon
mucosa, in agreement with the previous observations.28
Immunohistochemistry of Hsp60
To understand the mechanistic signiﬁcance of
Hsp60 in inﬂamed mucosa of patients with UC, we
assessed the immunopositivity for Hsp60 separately in
epithelium and lamina propria. Epithelial cellsFrespon-
sible for mucosal permeabilityFrepresent a barrier to
external stressors (eg, products of intestinal fermenta-
tion), whereas lamina propriaFin which vessels and
immune cells resideFis more susceptible to internal
stressors (eg, inﬂammation).29–33 Results are summarized
in Table 2 and Figure 4. Hsp60 positivity was localized in
the cytoplasm and the greatest numbers of positive cells
were consistently found in the epithelium. Moreover,
levels of Hsp60 were consistently higher at the time of
diagnosis (without diﬀerences between groups at this
time) as compared with the sixth month end point, at
which time a signiﬁcant (P<0.01) reduction in Hsp60 in
the treated groups was evident. Interestingly, at the sixth
month end point, we also found a signiﬁcant diﬀerence
between the 2 treated groups (P<0.05; Fig. 4). Hsp60
expression in normal mucosa (controls) was signiﬁcantly
(P<0.01) lower than in all the other groups. It is
noteworthy that the regression analyses between Hsp60
and inﬂammatory markers showed a linear correlation
between Hsp60 and CD68 levels in lamina propria (5-
ASA: r=+0.504; P=0.0234; 5-ASA+PB: r=+0.809;
P<0.0001, Fig. 5) but not between Hsp60 and CD3 or
CD4.
All together, these data support the view that Hsp60
is actively involved in UC pathogenesis as postulated
earlier.5 We would also like to suggest that the increase
of Hsp60 levels in relapsing patients is because of a
stimulus (or stimuli), which is yet to be identiﬁed
FIGURE 3. Representative images of inflammatory markers, that is, CD3-positive, CD4-positive, and CD68-positive cells, in
colon mucosa. Positive cells are brown. Nuclei were counterstained with hematoxylin and appear blue. Bar: approximately
100 mm.
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(mucosal cell stress induced by intestinal contents,
including bacteria?) and, as Hsp60 levels consistently
correlate with inﬂammation degree and disease severity,
we think there is a cause-eﬀect relationship between
Hsp60 and pathology.
Double Immunofluorescence of Hsp60
and CD68
In view of the results described in the preceding
paragraphs, and as it is known that CD68-positive macro-
phages have receptors for Hsp60, as TLR-434 and LOX-1,35
FIGURE 4. Immunohistochemical results and representative images of Hsp60-positive cells in colon mucosa. The top 2 panels
display bars showing the levels of Hsp60-positive cells in epithelium and lamina propria. Both treatments determined a significant
reduction of Hsp60 levels (P<0.01). Moreover, Hsp60 reduction in 5-ASA+PB treated patients was significantly greater (P<0.05)
than in patients receiving 5-ASA alone. The middle panels show representative images of the immunohistochemical results for
Hsp60. Positive cells are brown. Nuclei were counterstained with hematoxylin and appear blue. Bar: approximately 100 mm. The
bottom circular panels show at a magnification higher than that in the middle panels the immunohistochemical images for
Hsp60-positive cells in epithelium (Ep) and lamina propria (LP), demonstrating that the immunopositivity was localized in the
cytoplasm. Top panel bars: dark blue, 5-ASA at the time of diagnosis; red, 5-ASA+PB at the time of diagnosis; green, 5-ASA after 6
months; violet, 5-ASA+PB after 6 months; light blue, normal mucosa (controls). 5-ASA indicates 5-aminosalicylic acid
(mesalazine); Hsp, heat shock protein; PB, probiotics.
FIGURE 5. Hsp60-CD68 positive correlation. The regression plots show a significant positive correlation between Hsp60 and
CD68 levels in both 5-ASA (left panel) and 5-ASA+PB (right panel) treated groups. Pertinent correlation coefficients (Pearson r)
and “P ” values are indicated on top of each panel. 5-ASA indicates 5-aminosalicylic acid (mesalazine); Hsp, heat shock protein;
PB, probiotics.
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we decided to perform a double staining of these molecules
to verify if they colocalize in the same cells. Results are sum-
marized in Figure 6. Interestingly, most CD68 colocalized
with Hsp60 in cells in all the examined slides, and this
colocalization was most abundant at the time of diagnosis,
before treatment. The number of cells in which colocaliza-
tion of Hsp60 and CD68 occurred decreased signiﬁcantly
(P<0.01) at the sixth month end point in the 2 treated
groups, and this decrease was signiﬁcantly more pronounced
in the group that had received 5-ASA+PB than in the group
that received only 5-ASA, as shown in Figure 6. The number
of cells in which Hsp60 and CD68 colocalized was very low
in colon mucosa (not shown). These data on colocalization
of Hsp60-CD68 are in line with the immunohistochemical
results described above, and support the view that Hsp60
stimulates the immune system via interaction with CD68-
positive cells, for example, macrophages and, in turn,
ampliﬁes the inﬂammatory reaction.36–38
Immunoelectron Microscopy for Hsp60
Although Hsp60 is considered a mitochondrial
molecule, it has often been found in extramitochondrial
sites, including cytosol and cell membrane, especially in
pathologic conditions.16 To determine the intracellular
localization of Hsp60 in our group of patients and
controls, we resorted to immunoelectron microscopy. In
both the treated groups at the time of diagnosis, Hsp60
was present both in mitochondria and cytosol, whereas
FIGURE 6. Double immunofluorescence results for Hsp60 and CD68 and representative images. The bars in the top right panel
show the mean number of cells showing Hsp60-CD68 colocalization per high power field (400 ). This number was reduced
significantly after both treatments (P<0.01) and the reduction after 5-ASA+PB treatment was significantly greater (P<0.05) than
after treatment with 5-ASA alone. The top left panel and the bottom panels contain illustrative images of the double
immunofluorescence results for Hsp60 and CD68. Hsp60 appears red, CD68 appears green, and colocalization yellow/orange.
Nuclei are counterstained with Hoechst and appear blue. Colocalization is indicated by arrows. Hsp60 and CD68 often colocalized
in all specimens but the greatest numbers of cells showing Hsp60-CD68 colocalization were recorded in the samples taken before
treatment. Bar: approximately 100 mm. Top right panel bars: dark blue, 5-ASA at the time of diagnosis; red, 5-ASA+PB at the time
of diagnosis; green, 5-ASA after 6 months; violet, 5-ASA+PB after 6 months; light blue, normal mucosa (controls). 5-ASA indicates
5-aminosalicylic acid (mesalazine); Hsp, heat shock protein; PB, probiotics.
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after the treatment it was found only in mitochondria, as
illustrated in Figure 7. These results are in agreement with
the immunohistochemical data that showed reduced
levels of Hsp60 after each of the 2 treatments, suggesting
that the increased levels of Hsp60 before treatment were
due to abnormally high levels of the chaperonin in the
cytoplasm. As the presence of Hsp60 in the cytosol seems
to be a prerequisite for its secretion,19,39 we would like
to postulate that Hsp60 secretion occurs in relapsing UC
patients but not (or at least not to the same extent) for
those in remission. Reduced Hsp60 secretion would be
directly related to amelioration of symptoms as less
secreted Hsp60 would decrease Hsp60-macrophage inter-
action and, thus, reduce inﬂammation.
CONCLUSIONS
UC is a form of chronic, relapsing-remitting disease
with an autoimmune component of unknown origin.40,41
Severity of symptoms may vary from patient to patient, but
they include frequent episodes of diarrhea and rectal
bleeding.42 Clinic assessment is done by the Mayo Score24
ranging from 0 to 12. A score of 11 to 12 indicates a severe
disease treated surgically or with biologic drugs. A lower
score (4 to 10) indicates a mild-to-moderate disease often
treated with 5-ASA, which results in long disease-free
periods.42 More recently, a combined treatment with
5-ASA and probiotics demonstrated high eﬃcacy in
controlling symptoms and in extending the disease-free
periods,24,43,44 although a placebo eﬀect was also found.25
It has been postulated that, in UC, bacterial
pathogens have a role in triggering inﬂammation and
relapse.45,46 Commensal bacteria have a key role in
preventing colonization by pathogens of the colon muco-
sa and, thus, in avoiding disequilibrium of intestinal ﬂora
and its consequence, stress of intestinal mucosa.47 This is
the reason why we decided to compare the eﬀects of
treatments with either 5-ASA alone or in combination
with a probiotic.
FIGURE 7. Immunoelectron microscopy for Hsp60. In these 3 images, representative of our results, the black spots indicated by
arrows are 10 nm gold particles that show the presence of Hsp60. A, Control mucosa showing Hsp60 (arrows) inside
a mitochondrium (Mi). Only the “shadow” of mitochondria can be seen in our preparations because the Karnofsky fixative
we used for preservation of immunoreactivity of cells does not preserve their morphological details. B, Mucosal sample before
treatment showing a diffuse Hsp60 localization (some indicated by arrows) in the cytosol (Cy). The nucleus (Nu) is also visible. C,
Mucosal sample after treatment showing Hsp60 positivity (arrows) only in mitochondria. Hsp indicates heat shock protein.
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Our results showed that in both the groups of
patients, the treatment was eﬀective to reduce symptoms
and, thus, improve quality of life. This amelioration was
associated with a reduction of inﬂammatory components,
that is, CD3-positive, CD4-positive, and CD68-positive
cells. Moreover, when we compared the results of the
2 types of treatment, 5-ASA versus the combination
5-ASA+PB, we found a signiﬁcant diﬀerence between
the 2 groups for both clinical parameters and levels of
inﬂammatory cells. Patients receiving the combined treat-
ment responded better than those receiving only 5-ASA.
Thus, the probiotics showed a deﬁnite clinical eﬃcacy.
This is in agreement with a number of other studies that
showed eﬃcacy of other probiotics in the treatment of
IBD.25–28
In parallel, also Hsp60 levels were reduced after
treatment (as shown by immunohistochemistry, double
immunoﬂuorescence, and immunoelectron microscopy)
and this reduction was greater in patients treated with the
combination 5-ASA+PB than in those receiving only 5-
ASA. Interestingly, the levels of Hsp60 were found to
positively correlate with the levels of CD68, a marker of
macrophages and dendritic cells. In addition, before and
after the treatment, the great majority of CD68-positive
cells in lamina propria were also positive for Hsp60. This is
in agreement with the data from another laboratory48
showing that human Hsp60 is elevated in mononuclear cells
in the mucosa of patients with IBD, a ﬁnding that
prompted the authors to suggest that this chaperonin
might play a role in the initiation or maintenance of the
inﬂammatory process. It is known that CD68-positive
macrophages have receptors for Hsp60, like TLR-2, TLR-
4, CD14, and LOX-1.34,35 Thus, one may hypothesize that
Hsp60 is taken up by CD68-positive cells via those
receptors, something that ought to be tested experimentally.
However, one cannot rule out that Hsp60 is produced by
the macrophages or, even that both mechanisms, de novo
synthesis of hsp60 by CD68-positive cells and binding by
these cells of extracellular Hsp60 via surface receptors are at
the basis of our observations on colocalization of Hsp60
with CD68. In case there was binding of Hsp60 via surface
receptors, the expected consequence would be activation of
CD68-positive cells followed by inﬂammatory response, as
shown in the in vitro models.49–51 All together, these results
support the working hypothesis that Hsp60 can play a
decisive role in the pathogenesis of UC, and make Hsp60 a
promising candidate for the treatment of UC with anti-
chaperonin agents.
There is information in the literature suggesting that
Hsp60 plays a pathogenetic role as autoantigen in some
diseases with autoimmunity component, in which auto-
antibodies against the chaperonin may be present and
probably participate in the mechanism of tissue dam-
age.52–55 What we present here, in this work, is another,
distinct aspect of Hsp60 involvement in pathogenesis. Our
data pertain to a diﬀerent mechanism in which Hsp60 does
not act as autoantigen but as an immune-system signal
factor that triggers components of the innate immune
response, leading to inﬂammation rather than to antibody
production. The 2 mechanisms are not mutually exclusive;
on the contrary, both would contribute to initiation and
progression of mucosal damage and to re-initiation of
symptoms after a pause caused by treatment. However, the
2 mechanisms would call for diﬀerent treatment ap-
proaches. If Hsp60 acts as autoantigen and anti-Hsp60
autoantibodies are pathogenetic factors, therapeutic strate-
gies should include immune suppression. In contrast when
Hsp60 acts as an inﬂammation-trigger factor, anti-inﬂam-
matory agents should be considered as well as Hsp60
blockers to avoid interaction of the chaperonin with its
receptors on macrophages. There is however a point of
contact between the 2 pathogenetic mechanisms, and that is
the intestinal ﬂora. It has been suggested that bacterial
Hsp60 (GroEL) can invade the blood from its source in the
intestine and induce anti-GroEL antibodies that will cross-
react with the human Hsp60 and lead to autoimmune
reactions in various tissues, including in the colon
mucosa.56–58 Similarly, GroEL could penetrate the mucosal
tissue and interact with local macrophages and initiate
inﬂammation, adding to the eﬀect of endogenous Hsp60
freed from stressed and damaged cells. Thus, management
of the intestinal ﬂora would be of the essence in the
treatment of UC. Our data with probiotics would tend to
support this hypothesis and lend support to treatment
regimens that include improvement of the intestinal
microbiota.
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